Article

Discovery of a novel human antibody VH domain with potent activity against mesothelin expressing cancer cells in both CAR T-cell and antibody drug conjugate formats

2022-04-08

Abstract excerpt

Antibody based therapeutics targeting mesothelin (MSLN) have shown limited anticancer activity in clinical trials. Novel antibodies with high affinity and better therapeutic properties are needed. In the current study, we have isolated and characterized a novel VH domain 3C9 from a large size human immunoglobulin heavy chain variable (VH) domain library. 3C9 exhibited high affinity [KD (dissociation constant) < 3...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 43e1ee39-0c28-5d5c-852a-06286d12e5c0
DOI: 10.1101/2022.04.07.487497

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery of a novel human antibody VH domain with potent activity against mesothelin expressing cancer cells in both CAR T-cell and antibody drug conjugate formatsDOI 10.1101/2022.04.07.487497Read

Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.Semantic proximity Read

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22Semantic proximity Read

Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors.Semantic proximity Read

A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.Semantic proximity Read

Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugationSemantic proximity Read

Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examplesSemantic proximity Read

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell VectorSemantic proximity Read

Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung CancerSemantic proximity Read

Expression, purification, and characterization of engineered antibody CH2 and VH domains.Semantic proximity Read

Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.Semantic proximity Read

Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T CellsSemantic proximity Read

MesothelinSemantic proximity Read